Clinical trial
Alemtuzumab and Rituximab in Treating Patients With High-Risk, Early-Stage…
NCT00436904 · Mayo Clinic, Other · Completed
Key facts
| NCT number | NCT00436904 |
|---|---|
| Title | Alemtuzumab and Rituximab in Treating Patients With High-Risk, Early-Stage Chronic Lymphocytic Leukemia |
| Official title | Antibody Therapy With Alemtuzumab and Rituximab for Initial Treatment of High Risk Chronic Lymphocytic Leukemia |
| Lead sponsor | Mayo Clinic, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Leukemia |
| Intervention type | Drug |
| Interventions | Alemtuzumab, Rituximab |
| Enrollment | 30 |
| Start date | Dec 1, 2004 |
| Primary completion | Jul 1, 2008 |
| Completion | Nov 1, 2011 |
| First posted | Feb 19, 2007 |
| Last update posted | Dec 1, 2011 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: